ArticleHealth science reports2025
Impact of
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Impact ofHealth science reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Gemcitabine-based treatment is normally used for pancreatic ductal adenocarcinoma (PDAC). Genetic polymorphisms of the Kirsten rat and novel oncogene homologue (KRAS) variant contribute to the survival and prognosis of patients with PDAC. We aimed to reveal a potential gene signature against the background of KRAS mutations in PDAC after gemcitabine-based treatment. Methods: In this study, 35 PDAC patients were enrolled for analysis. The highly mutated genes were screened out. K‒M survival plots were then used to compare the effects of different KRAS variants on survival. The total expression data related to different KRAS genetic variants and PDAC samples treated with gemcitabine were extracted from the Cancer Genome Atlas Program (TCGA) and the Gene Expression Omnibus (GEO), respectively. The differentially expressed genes (DEGs) were identified, and the Gene Set Enrichment analysis (GSEA) was then performed. The hub genes between the selected TCGA and GEO data sets were extracted. K-M analysis and Linkomics-based method were used to evaluate the prognostic value of the hub genes. GSEA and the Tumor Immune Dysfunction and Exclusion (TIDE) database-based analysis were also employed. Results: KRAS Glycine (G) 12 Arginine (R) mutations are associated with shorter Progression-Free-Survival (PFS) than the other two KRAS mutational types. Five hub genes were screened out according to the above method. After the K‒M analysis, only Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.